Skip to main content
Premium Trial:

Request an Annual Quote

In Connecticut, Bigger Bucks for Biotech: R&D Up 18 Percent In 2001

NEW YORK, March 27-Biotech investment jumped about 18 percent last year in Connecticut, according to an analysis released yesterday evening by an industry group.

 

In 2001, biomedical R&D spending in Connecticut climbed to $3.6 billion, up from $3.1 billion in 2000.

 

Most of that investment came from pharmaceutical companies, which plowed nearly $3 billion into the sector in 2001. Biotech firms accounted for only about $277 million of the total research investment.

 

The sector added roughly 500 new jobs last year in the state, for a total Connecticut biomedical labor force of about 16,500.

 

The analysis, part of an annual economic report, was conducted by Connecticut United for Research Excellence, a state umbrella group for biomedical researchers in industry and academia.

 

Research firms in the survey included Boehringer Ingelheim, Bristol-Myers Squibb, Cellular Genomics, CuraGen Corporation, Genaissance Pharmaceuticals, and Protein Sciences Corporation. Academic institutes included the University of Connecticut and Yale University.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.